Cargando…

Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound

Objective: To evaluate the value of dynamic contrast-enhanced ultrasound (DCE-US) and quantitative parameters in early prediction of tumor response to chemoradiotherapy (CRT) in patients with locally advanced pancreatic ductal adenocarcinoma (LAPC). Patients and Methods: In this prospective study, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Xiu-Yun, Guo, Xi, Zhang, Qi, Qiu, Yi-Jie, Zuo, Dan, Chen, Sheng, Tian, Xiao-Fan, Zhou, Yu-Hong, Dong, Yi, Wang, Wen-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689529/
https://www.ncbi.nlm.nih.gov/pubmed/36359506
http://dx.doi.org/10.3390/diagnostics12112662
_version_ 1784836557955399680
author Lu, Xiu-Yun
Guo, Xi
Zhang, Qi
Qiu, Yi-Jie
Zuo, Dan
Chen, Sheng
Tian, Xiao-Fan
Zhou, Yu-Hong
Dong, Yi
Wang, Wen-Ping
author_facet Lu, Xiu-Yun
Guo, Xi
Zhang, Qi
Qiu, Yi-Jie
Zuo, Dan
Chen, Sheng
Tian, Xiao-Fan
Zhou, Yu-Hong
Dong, Yi
Wang, Wen-Ping
author_sort Lu, Xiu-Yun
collection PubMed
description Objective: To evaluate the value of dynamic contrast-enhanced ultrasound (DCE-US) and quantitative parameters in early prediction of tumor response to chemoradiotherapy (CRT) in patients with locally advanced pancreatic ductal adenocarcinoma (LAPC). Patients and Methods: In this prospective study, patients with biopsy-proved and histopathologically proved LAPC who underwent regular CRT were recruited. DCE-US evaluations were performed before and four months after CRT. SonoVue-enhanced contrast-enhanced ultrasound (CEUS) was performed by an ultrasound system (ACUSON Sequoia; Siemens Medical Solutions, USA) equipped with a 5C1 MHz convex array transducer. Time–intensity curves were created by VueBox software (Bracco, Italy), and various DCE-US quantitative parameters were obtained. Taking Response Evaluation Criteria in Solid Tumors (RECIST) based on computed tomography (CT) or magnetic resonance imaging (MRI) as the gold standard, DCE-US parameters were compared between the treatment responder group (RG) and non-responder group (NRG). The correlation between the DCE-US parameters and the serum carbohydrate antigen 19-9 (CA 19-9) level was also analyzed. Results: Finally, 21 LAPC patients (mean age 59.3 ± 7.2 years) were included. In comparing the RG (n = 18) and NRG (n = 3), no significant change could be found among the mean size of the lesions (31.2 ± 8.1 mm vs. 27.2 ± 8.3 mm, p = 0.135). In comparing the TICs between the two groups, the LAPC lesions in the RG took a longer time to reach peak enhancement and to wash out. Among all the DCE-US parameters, RT (rise time), WiAUC (wash-in area under the curve), WoAUC (wash-out area under the curve) and WiWoAUC (wash-in and wash-out area under the curve) decreased significantly after CRT in the RG (p < 0.05). The RT ratio, WiAUC ratio, WoAUC ratio and WiWoAUC ratio were closely correlated with the change in serum CA 19-9 level in the RG (p < 0.05). Conclusion: DCE-US might be a potential imaging method for non-invasive follow-up for early response in LAPC patients treated by CRT.
format Online
Article
Text
id pubmed-9689529
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96895292022-11-25 Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound Lu, Xiu-Yun Guo, Xi Zhang, Qi Qiu, Yi-Jie Zuo, Dan Chen, Sheng Tian, Xiao-Fan Zhou, Yu-Hong Dong, Yi Wang, Wen-Ping Diagnostics (Basel) Article Objective: To evaluate the value of dynamic contrast-enhanced ultrasound (DCE-US) and quantitative parameters in early prediction of tumor response to chemoradiotherapy (CRT) in patients with locally advanced pancreatic ductal adenocarcinoma (LAPC). Patients and Methods: In this prospective study, patients with biopsy-proved and histopathologically proved LAPC who underwent regular CRT were recruited. DCE-US evaluations were performed before and four months after CRT. SonoVue-enhanced contrast-enhanced ultrasound (CEUS) was performed by an ultrasound system (ACUSON Sequoia; Siemens Medical Solutions, USA) equipped with a 5C1 MHz convex array transducer. Time–intensity curves were created by VueBox software (Bracco, Italy), and various DCE-US quantitative parameters were obtained. Taking Response Evaluation Criteria in Solid Tumors (RECIST) based on computed tomography (CT) or magnetic resonance imaging (MRI) as the gold standard, DCE-US parameters were compared between the treatment responder group (RG) and non-responder group (NRG). The correlation between the DCE-US parameters and the serum carbohydrate antigen 19-9 (CA 19-9) level was also analyzed. Results: Finally, 21 LAPC patients (mean age 59.3 ± 7.2 years) were included. In comparing the RG (n = 18) and NRG (n = 3), no significant change could be found among the mean size of the lesions (31.2 ± 8.1 mm vs. 27.2 ± 8.3 mm, p = 0.135). In comparing the TICs between the two groups, the LAPC lesions in the RG took a longer time to reach peak enhancement and to wash out. Among all the DCE-US parameters, RT (rise time), WiAUC (wash-in area under the curve), WoAUC (wash-out area under the curve) and WiWoAUC (wash-in and wash-out area under the curve) decreased significantly after CRT in the RG (p < 0.05). The RT ratio, WiAUC ratio, WoAUC ratio and WiWoAUC ratio were closely correlated with the change in serum CA 19-9 level in the RG (p < 0.05). Conclusion: DCE-US might be a potential imaging method for non-invasive follow-up for early response in LAPC patients treated by CRT. MDPI 2022-11-02 /pmc/articles/PMC9689529/ /pubmed/36359506 http://dx.doi.org/10.3390/diagnostics12112662 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lu, Xiu-Yun
Guo, Xi
Zhang, Qi
Qiu, Yi-Jie
Zuo, Dan
Chen, Sheng
Tian, Xiao-Fan
Zhou, Yu-Hong
Dong, Yi
Wang, Wen-Ping
Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound
title Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound
title_full Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound
title_fullStr Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound
title_full_unstemmed Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound
title_short Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound
title_sort early assessment of chemoradiotherapy response for locally advanced pancreatic ductal adenocarcinoma by dynamic contrast-enhanced ultrasound
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689529/
https://www.ncbi.nlm.nih.gov/pubmed/36359506
http://dx.doi.org/10.3390/diagnostics12112662
work_keys_str_mv AT luxiuyun earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound
AT guoxi earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound
AT zhangqi earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound
AT qiuyijie earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound
AT zuodan earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound
AT chensheng earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound
AT tianxiaofan earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound
AT zhouyuhong earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound
AT dongyi earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound
AT wangwenping earlyassessmentofchemoradiotherapyresponseforlocallyadvancedpancreaticductaladenocarcinomabydynamiccontrastenhancedultrasound